Skip to main content
Premium Trial:

Request an Annual Quote

Skyline, Clavis Partner on Biomarkers for AML Drug

NEW YORK (GenomeWeb News) – Skyline Diagnostics and Clavis Pharma today announced a deal to investigate gene expression biomarkers that may help determine which patients will benefit from a drug compound being developed for treating acute myeloid leukemia.

Under the agreement Skyline will investigate the biomarkers for use with Clavis' elacytarabine, a novel elaidic acid derivative of cytarabine currently undergoing the CLAVELA phase III study for treating patients with relapsed/refractory AML. The study is an open-label, randomized, controlled trial to demonstrate the effectiveness of elacytarabine compared to other current therapies, according to Clavis' website.

Athos Gianella-Borradori, chief medical officer of the Oslo, Norway-based drug firm, said in a statement that Skyline's expertise "will be instrumental in searching for gene expression patterns that can be utilized in the further biomarker program for elacytarabine."

Financial and other terms of the deal were not disclosed.

Based in Rotterdam, The Netherlands, Skyline develops array-based diagnostics tests.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.